Biosimilar deals forge a trio of partnerships
Aflurry of activity in the biosimilar licensing arena has resulted in three new partnerships being struck. Lupin and Mylan have entered a deal for Mylan to sell the Indian firm’s etanercept candidate in various worldwide territories; Prestige Biopharma and Alvogen have agreed a licensing and supply arrangement on Prestige’s trastuzumab in central and eastern Europe (CEE); and Shanghai Henlius Biotech will allow Accord to sell its trastuzumab in more than 70 countries around the globe.
You may also be interested in...
Accord And Henlius Broaden Trastuzumab Alliance
Shanghai Henlius Biotech and Accord Healthcare have broadened their collaboration on trastuzumab, with the Chinese company licensing its Zercepac biosimilar to Accord in the US and Canada. Meanwhile, Accord has launched a Pelgraz pegfilgrastim pre-filled injector and patient app in the UK.
Isatuximab EU Approval Decision Due
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Alvotech And Prestige Strike Biosimilar Manufacturing Deal
Alvotech and Prestige Biopharma have announced a new contract manufacturing partnership for one of Prestige’s biosimilar candidates.